HAYA Therapeutics
HAYA Therapeutics is a precision medicines company developing RNA-guided programmable therapeutics targeting the regulatory genome for serious health conditions including cardiovascular disease and cancer. The company is using its innovative cell-state modifying platform to gain novel insights into the biology of long non-coding RNAs (lncRNAs), the ‘dark genomes’ information processing features and ‘source code’. HAYA’s lead therapeutic candidate is HTX-001, an antisense oligonucleotide targeting Wisper, which is a tissue and cell-specific cardiac lncRNA known to play a role in heart failure. The company is also developing a pipeline of lncRNA-targeting candidates for the cell-specific treatment of diseases in other tissues, including the lungs and the microenvironment of solid tumor cancers. Headquartered at the life sciences park Biopôle in Lausanne, Switzerland with laboratory facilities at JLABS @ San Diego, HAYA is led by a world-class team of experts in programmable and precision RNA-targeted therapeutics and is supported by a strong investor consortium. HAYA’s mission is to identify and develop breakthrough disease-modifying therapeutics with the potential for greater efficacy, safety, and accessibility than existing treatments.
HAYA Therapeutics
Haya Therapeutics develops RNA therapies targeting the dark genome to reprogram disease-driving cell-states for underserved rare and chronic diseases.
About
Needs Assessment
Active buying signals and potential business opportunities
Technology Requirements
Tools for lncRNA discovery, target validation, and drug development.
Platforms for multi-omic data analysis and drug screening.
Data encryption, pseudonymization tools, logging systems, access control mechanisms.
Proprietary RNA platform.
Innovative therapeutic strategies for solid tumors.
Service Requirements
Contract research organizations (CROs) for preclinical and clinical development; manufacturing support.
Data protection consulting, legal compliance services.
Clinical trial development.
Drug discovery and development services.
Developing therapies for fibrosis, cardiovascular diseases, obesity, metabolic conditions, and aggressive solid tumors.
Precision medicines development, RNA-based therapeutics research.
Infrastructure Requirements
Secure IT environment.
Secure networks, data storage.
Swiss campus in Lausanne, U.S. location.
Reliable IT infrastructure.
Talent Requirements
Scientists with expertise in lncRNA biology, regulatory genome, and ASO technologies.
Bioinformaticians with experience in multi-omics data analysis and integration.
Expertise in cardiology, genetics, and molecular biology.
AI Insights
Growth Trajectory
With locations in Lausanne, San Diego, and Montreal and a pipeline expanding beyond heart disease, Haya Therapeutics shows strong growth potential in the RNA therapeutics market, especially with its focus on the relatively unexplored 'dark genome'.
Market Opportunity
Haya Therapeutics has a strong market opportunity in developing novel RNA therapies targeting lncRNAs for diseases with limited treatment options, positioning them as a pioneer in the 'dark genome' therapeutic space.
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats